Navigation Links
Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
Date:12/17/2013

Austin, TX and Oklahoma City, OK (PRWEB) December 17, 2013

Emergent Technologies, Inc. a Texas-based innovation solutions company specializing in the commercialization of life and material science technologies; announced today that it has hired Gregory Daniel Frank, Ph.D. as President of Pure Protein, LLC and Pure MHC, LLC. Dr. Frank is a seasoned business development professional and immunology expert with vast experience sourcing, structuring, negotiating, and closing agreements for licensing, strategic alliances, and discovery and development services in the pharmaceutical industry.

“The recent forming of Pure MHC and the increasing number of partnership opportunities made the timing right to bring Dr. Frank on board,” said Thomas Harlan, CEO of Pure Protein, Pure MHC and Emergent Technologies, Inc., the innovation solutions company that funds and manages both companies. “Gregory’s comprehensive background in business development, drug discovery and development, and strong alliance management skills will help take Pure Protein and Pure MHC to the next level.”

“Thomas Harlan has a unique approach to building companies and creating value that is unparalleled in this industry. I’m excited to be part of his team,” said Gregory.

Dr. Frank most recently served as Director, Business Development at XBiotech USA, Inc. an Austin, TX based company developing novel antibody therapies, where he had sole responsibility for all aspects of partnering the company’s clinical and preclinical assets and for corporate development that included raising capital for ongoing operations, building a manufacturing facility, and conducting a Phase III trial. Previously, he spent 10 years at SRI International, Biosciences as Director, Business Development and Marketing where he was involved in business development and marketing for all aspects of SRI's business model, successfully growing basic research, drug discovery, and contract research (CRO) services and learning the intricacies of value creation. Dr. Frank earned his Ph.D. in Immunology from Stanford University School of Medicine and his B.A. in Biology from the University of California at Santa Cruz.

About Pure Protein

Pure Protein, LLC has developed and patented several soluble HLA protein reagents and uses of those reagents in therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Transplant Solutions, L.L.C., a subsidiary of Pure Protein, is using sHLA protein to develop multiple diagnostics, devices, and therapeutics to eliminate rejection in organ transplants. Pure Vaccine Solutions, L.L.C (PVS), another subsidiary of Pure Protein, is an immunology company focused on methods to discover MHC-based diagnostic and therapeutic targets specific to infectious diseases and cancers. Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information, visit http://www.pureproteinllc.com.

About Pure MHC

Pure MHC, LLC was formed as a single market facing entity uniting the complementary technologies of PVS and Receptor Logic Inc. Pure MHC uses proprietary technology to discover novel targets to treat infectious disease and cancer and then to drug those targets in multiple ways, in particular using its proprietary technology to generate T-cell receptor mimicking monoclonal antibodies to those novel targets. For more information visit http://www.puremhc.com.

About Emergent Technologies, Inc.

Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages,develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit http://www.emergenttechnologies.com.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11427433.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
2. Gregory Raupp Appointed Director of MacroTechnology Works at Arizona State University to Advance Flexible Electronics and Manufacturing
3. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
4. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
5. Worcester Polytechnic Institute’s Tanja Dominko Named Slovenian Ambassador of Science for 2013
6. Finalists Named for 2014 Prism Awards for Photonics Innovation
7. Fidelis Companies Named in 2014 Best Companies to Work for in Texas
8. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
9. CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
10. OriGene named to Deloitte’s 2013 North America Technology Fast 500
11. Three World-Renowned Philadelphia Scientists Are Named As Recipients Of The 2013 John Scott Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... This June ... Tampa, Florida. As an exclusive sales and service provider of the ALPINION line, ... 2016 is the premier conference for healthcare technology management. The event draws more than ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences ... its first three targets, it has identified a fourth in a series of ... the development and progression of Alzheimer’s disease (AD). , “This discovery ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
Breaking Biology Technology:
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):